Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

In a phase II trial of nivolumab in advanced thymic carcinoma (UMIN000022007), long SD (SD for more than 24 weeks) was seen in three patients and irAE (Gr2 or higher) was seen in four patients among 15 patients. Here, we report preplanned comprehensive biomarker analyses. We obtained tumor samples f...

Full description

Bibliographic Details
Main Authors: Yuki Katsuya, Shigehisa Kitano, Makiko Yamashita, Mayu Ouchi, Shigehiro Yagishita, Akinobu Hamada, Hiromi Nakamura, Fumie Hosoda, Tatsuhiro Shibata, Noriko Motoi, Takayuki Nakayama, Takashi Seto, Shigeki Umemura, Yukio Hosomi, Miyako Satouchi, Makoto Nishio, Toshiyuki Kozuki, Toyoaki Hida, Yuichiro Ohe, Hidehito Horinouchi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
thymic carcinoma
nivolumab
immunogenicity
biomarker
peripheral blood mononuclear cell (PBMCs)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.966527/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.966527/full

Similar Items